LocationMadrid, Spain
TypeFoundation / Research Institute
Founded2005
AffiliationCarlos III Health Institute, Ministry of Health
FocusAlzheimer's, Parkinson's, ALS, FTD
Website[fundacioncien.es](https://www.fundacioncien.es)
The CIEN Foundation (Centro de Investigación de Enfermedades Neurológicas) is a leading Spanish research institution dedicated to advancing the understanding, diagnosis, and treatment of neurodegenerative diseases. Based in Madrid, Spain, the CIEN Foundation operates as a major center for translational neuroscience research focused on Alzheimer's disease, Parkinson's disease, and other neurological disorders[1].
Established in 2005 as a collaborative initiative between the Spanish Ministry of Health and the Carlos III Health Institute (ISCIII), the CIEN Foundation was created to establish a center of excellence for neurodegenerative disease research in Spain. The foundation represents Spain's primary contribution to European and international neurodegeneration research networks, contributing significantly to the understanding of disease mechanisms, biomarker development, and therapeutic strategies.
¶ Foundation and Mission (2005-2010)
The CIEN Foundation was established in 2005 with a specific mission to advance neurodegenerative disease research in Spain. The founding was driven by several factors:
- National Need: Spain had limited infrastructure for neurodegenerative disease research compared to other European countries
- Aging Population: Spain's rapidly aging population created urgent need for AD and PD research
- European Integration: Spain sought to participate fully in European research consortia
The initial focus was on establishing core research infrastructure and developing national research networks. Key early achievements included:
- Establishment of the Queen Sofia Spanish Alzheimer's Centre as the flagship research facility
- Development of clinical research infrastructure for clinical trials
- Creation of the Spanish Brain Bank network
¶ Expansion and International Recognition (2010-2020)
During this period, CIEN Foundation achieved international recognition:
- ADNI Membership: Joined the Alzheimer's Disease Neuroimaging Initiative, providing Spanish cohort data to international analyses[2]
- EADC Participation: Became a founding member of the European Alzheimer's Disease Consortium[3]
- Clinical Trial Hub: Established Spain as a key site for international pharmaceutical clinical trials
- Research Output: Published extensively in high-impact journals
The current period has focused on:
- Precision medicine approaches
- Biomarker validation in Spanish populations
- Integration of multi-omics methodologies
- Development of the Spanish Neurodegeneration Research Platform
The flagship facility at CIEN, the Queen Sofia Spanish Alzheimer's Centre, represents one of the most comprehensive neurodegeneration research centers in Spain[4]. This state-of-the-art facility houses:
Neuroimaging Suite:
- 3T MRI scanner dedicated to research
- PET/CT scanner for amyloid and tau imaging
- Advanced image analysis laboratory
- Longitudinal neuroimaging database
Clinical Research Unit:
- Dedicated clinical trial facilities
- Cognitive assessment laboratory
- Clinical sample collection and processing
- Patient recruitment and registry
Brain Bank:
- Comprehensive brain tissue collection
- Neuropathological characterization
- Molecular biology laboratories
- Tissue sharing with national and international researchers
Animal Research Facility:
- Rodent models of neurodegeneration
- Behavioral testing facilities
- Surgery suites for stereotactic procedures
Molecular Neurology Laboratory:
- Genetic analysis and sequencing facilities
- Protein biochemistry equipment
- Cell culture facilities
- Single-cell analysis capabilities
Neuropathology Laboratory:
- Histopathology services
- Immunohistochemistry
- Stereological analysis
- Tissue microarray production
Cognitive Neuroscience Laboratory:
- Neuropsychological testing facilities
- Electrophysiology (EEG) equipment
- Eye-tracking capabilities
- Virtual reality behavioral paradigms
Biomedical Statistics Unit:
- Statistical consultation
- Bioinformatics support
- Database management
- Clinical trial design
The Alzheimer's disease research program at CIEN represents the most comprehensive AD research effort in Spain:
Biomarker Development:
CIEN researchers have made significant contributions to biomarker research, focusing on:
- CSF Biomarkers: Validation of Aβ42, total tau, and phosphorylated tau in Spanish populations
- Blood Biomarkers: Development of plasma p-tau assays for clinical use
- Imaging Biomarkers: Amyloid and tau PET standardization
- Digital Biomarkers: Cognitive testing apps and wearable integration
Clinical Research:
- Participation in over 50 clinical trials for AD therapeutics
- Observational cohort studies following 2,000+ patients
- Prevention trials in at-risk populations
- Biomarker validation studies
Genetic Studies:
- Characterization of Spanish population genetics
- Identification of novel risk factors
- Investigation of protective variants
- Family-based studies
Key Research Groups:
| Group |
Focus |
Key Personnel |
| Biomarkers |
CSF and blood markers |
Dr. Juan L. Molinuevo |
| Neuroimaging |
MRI and PET analysis |
Dr. Alberto Lleó |
| Clinical Trials |
Therapeutic development |
Dr. Mercè Boada |
| Genetics |
Population genetics |
Dr. Ramón Cacabelos |
¶ Parkinson's Disease and Movement Disorders
The Parkinson's disease research program encompasses basic and clinical research:
Alpha-Synuclein Research:
- Propagation mechanisms of α-synuclein pathology
- Strain diversity in Lewy body diseases
- CSF biomarker development
- Immunotherapy approaches
Clinical PD Research:
- Characterization of motor and non-motor symptoms
- Deep brain stimulation optimization
- Disease progression biomarkers
- Rehabilitation interventions
Other Movement Disorders:
- Multiple System Atrophy (MSA)
- Progressive Supranuclear Palsy (PSP)
- Corticobasal Degeneration (CBD)
- Dystonia and tremor disorders
Frontotemporal Dementia:
- Clinical phenotype characterization
- Genetic studies (GRN, C9orf72, MAPT)
- Biomarker development
- Clinical trials
Amyotrophic Lateral Sclerosis (ALS):
- Spanish ALS registry
- Biomarker studies
- Clinical trial participation
- Stem cell research
Multiple Sclerosis:
- Neuroimmunology research
- Demyelination mechanisms
- Progressive MS characterization
CIEN Foundation coordinates the Spanish Neurodegeneration Research Network (Rede de Investigación en Neurodegeneración), which encompasses:
Academic Partners:
- Universidad Autónoma de Madrid
- Universidad de Barcelona
- Universidad de Pamplona
- Universidad de Sevilla
- Universidad de Valencia
Hospital Partners:
- Hospital Clínic de Barcelona
- Hospital Ramón y Cajal (Madrid)
- Hospital Universitario de Madrid
- Hospital Virgen del Rocío (Seville)
Research Institutes:
- Instituto de Biomedicina y Parasitología (CSIC)
- Instituto de Neurociencias (CSIC)
- Basque Center for Applied Mathematics
The network coordinates:
- Multicenter clinical studies
- Shared sample collection
- Joint funding applications
- Training programs
- Publication coordination
CIEN maintains active participation in European research initiatives:
European Alzheimer's Disease Consortium (EADC):
- Regular data sharing and collaborative publications
- Joint clinical trial design
- Biomarker standardization efforts
- Early-phase trial networks
Joint Programme - Neurodegenerative Disease Research (JPND):
- Large-scale collaborative grants
- Methodological standardization
- Data harmonization
- Training exchanges
European Medicines Agency (EMA):
- Regulatory interactions
- Trial protocol development
- Biomarker qualification
Alzheimer's Disease Neuroimaging Initiative (ADNI):
CIEN contributes Spanish cohort data to ADNI, participating in:
- Data contribution and standardization
- Analysis working groups
- Publication collaborations
- Method development
International Parkinson's Disease Genomics Consortium (IPDGC):
- Genetic data sharing
- Replication studies
- Meta-analyses
Global Alzheimer's Association Interactive Network (GAAIN):
- Data sharing platform participation
- Method development
- USA: NIH-funded collaborations with US institutions
- UK: Partnerships with UCL and Oxford
- Germany: DZNE collaboration
- France: INSERM partnerships
- Italy: EUREKA network membership
¶ Funding and Financial Support
Primary Sources:
- Carlos III Health Institute (ISCIII): Main governmental funder
- Spanish Ministry of Science: Research grants
- Regional governments: Andalusia, Catalonia, Madrid
- Spanish Foundation for Science (FECYT)
Grant Programs:
- FIS (Fondo de Investigación en Salud)
- AES (Acción Estratégica en Salud)
- RETOS Colaboración
- Horizon Europe framework program
- European Research Council (ERC) grants
- COST Actions
- European Regional Development Fund (ERDF)
¶ Foundation and Industry Support
- "La Caixa" Foundation
- Grifols partnership
- Roche collaboration
- Lilly research agreements
- Other pharmaceutical partnerships
| Category |
Approximate Annual Amount |
| National funding |
€8-10 million |
| European funding |
€3-5 million |
| Industry partnerships |
€2-3 million |
| Foundation support |
€1-2 million |
| Total |
€14-20 million |
¶ Training and Education
CIEN offers training in neurodegenerative disease research through:
PhD Programs:
- Affiliated with Universidad Autónoma de Madrid
- Neuroscience doctoral program
- Biomedical research program
- Average completion time: 4-5 years
Master's Programs:
- Master's in Neuroscience
- Master's in Clinical Research
- Specialized courses in neurodegeneration
- Individual postdoctoral positions
- Postdoctoral fellowship programs
- Training in specific methodologies
- Career development workshops
- Neurology resident rotations
- Clinical fellowship program
- Clinical trial methodology training
- Neuropsychology training
- Short-term research visits
- Collaborative projects
- Training exchanges
- Sabbatical opportunities
¶ Clinical Services and Patient Care
CIEN-affiliated clinicians provide comprehensive memory disorder services:
Diagnostic Services:
- Comprehensive neuropsychological assessment
- Neuroimaging (MRI, PET)
- CSF biomarker analysis
- Genetic counseling
- Differential diagnosis
Treatment Services:
- Pharmacological management
- Non-pharmacological interventions
- Caregiver support
- Clinical trial enrollment
- Specialized PD care
- Deep brain stimulation programming
- Botulinum toxin treatment
- Rehabilitation services
CIEN serves as a major clinical trial site in Spain:
Active Trial Types:
- Disease-modifying therapies (anti-amyloid, anti-tau)
- Symptomatic treatments
- Biomarker studies
- Prevention trials
Trial Networks:
- European Alzheimer's Disease Consortium trials
- Pharma-sponsored Phase II/III trials
- Independent academic trials
CIEN has contributed significantly to biomarker validation in European populations:
CSF Biomarkers:
- Demonstrated CSF Aβ42/tau ratio effectiveness
- Validated European reference values
- Contributed to standardization efforts
Imaging Biomarkers:
- Amyloid PET centiloid standardization
- Tau PET validation in European cohorts
- Established Spanish Alzheimer's registry
- Characterized population-specific disease patterns
- Developed clinical care standards
- Trained 50+ PhD students
- Postdoctoral researchers in leading positions
- Clinical fellows in academic and industry positions
¶ Future Directions and Strategic Priorities
- Precision Medicine: Biomarker-driven patient stratification
- Multi-omics Integration: Genomics, transcriptomics, proteomics
- Digital Health: Wearable and digital biomarkers
- Therapeutic Development: Early-phase trial capabilities
- Data Science: AI/ML integration
- New research building (planned)
- Enhanced computing infrastructure
- Expanded biobank capacity
- Advanced imaging capabilities
- Enhanced ADNI participation
- New European partnerships
- Leadership in EADC
- Global research network expansion
¶ Governance and Leadership
CIEN Foundation
├── Board of Directors
│ └── Representatives from Ministry of Health, ISCIII
├── Scientific Director
│ └── Research Programs
├── Administrative Director
│ └── Operations
└── Research Divisions
├── Alzheimer's Disease
├── Parkinson's Disease
├── Other Neurodegenerative
└── Support Units
- International scientific advisory board
- Patient and family advisory council
- Industry advisory group
¶ Notable Publications and Scientific Impact
- 100+ publications annually
- High-impact journals (Nature, Brain, Neurology)
- Significant citation impact
- Biomarker validation studies
- Clinical trial publications
- Genetic association studies
- Review articles and guidelines